Bachem
  • Products & Services
    • CMC Development
      • Peptide NCEs
      • Oligonucleotide NCEs
    • Commercial API
      • Commercial NCEs
      • Commercial Generics
    • Research & Specialties
      • Catalog Peptides
      • Custom Peptide Synthesis
      • Amino Acid Derivatives
      • Diagnostics
      • Cosmetic Peptides
    • Services & Capabilities
      • Project Management
      • Quality & Regulatory
      • Analytical capabilities
      • GMP Production
      • Research Grade Production
      • Supply & vertical integration
  • About Bachem
    • Company overview
      • Our Purpose
      • Our vision & strategy
      • Our Leadership
      • Our History
      • Our Showroom
      • Our Locations
    • Innovation
      • Innovation matters
      • Innovation collaborations
    • Sustainability
      • People & culture
      • Safeguarding the environment
      • Acting ethically
    • Investors & Media
      • Reports & Presentations
      • Financial events
      • Media Library
      • Press archive
  • News & Events
    • Events
    • News
    • Showroom
  • Knowledge Center
  • Careers
  • Contact
  • T
Select Page
Bachem raises CHF 108.1 million through capital increase to accelerate its growth plans

Bachem raises CHF 108.1 million through capital increase to accelerate its growth plans

Mar 10, 2023 | Ad-hoc, Featured news, Finance, News, Press

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL Following yesterday’s...
Bachem launches an accelerated bookbuilding for the placement of up to 1.25 million new shares to accelerate its growth plans

Bachem launches an accelerated bookbuilding for the placement of up to 1.25 million new shares to accelerate its growth plans

Mar 9, 2023 | Ad-hoc, Finance, News, Press

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL Share placement of up...
Bachem achieves solid growth in 2022

Bachem achieves solid growth in 2022

Mar 7, 2023 | Ad-hoc, Featured news, Finance, News, Press

Bachem signs long-term cooperation agreement for the development and supply of peptides

Bachem signs long-term cooperation agreement for the development and supply of peptides

Mar 3, 2023 | Ad-hoc, Featured news, Finance, News, Press

Framework agreement signed with a total committed order volume of more than CHF 500 million for the period of 2027-2031 following a joint development project. Order volumes diversify the order book for building “K” in Bubendorf, Bachem’s largest-scale production...
Bachem signs long-term follow-on contract for peptides

Bachem signs long-term follow-on contract for peptides

Dec 16, 2022 | Ad-hoc, Featured news, Finance, News, Press

Contract signed with a total minimum order volume of CHF 1 billion over a five-year period from 2025-2029. Companies agree to maintain customer confidentiality. Bachem Group (SIX: BANB) today announced the signing of a further work order for the delivery of large...
Bachem signs large volume contracts for peptides

Bachem signs large volume contracts for peptides

Sep 20, 2022 | Ad-hoc, Featured news, Finance, News, Press

Two contracts signed with order volumes of CHF 25 million in 2023 and CHF 150 million in 2024. Potential for significantly larger orders for the following years under negotiation. Companies agree to maintain customer confidentiality. Bachem Group (SIX: BANB) today...
« Older Entries
Newsletter registration
General Conditions
Legal Statement
Privacy Policy
Imprint
Contact
Q

Advanced Search

  •  

  •  

  •  

  •  

  •  

Manage Cookie Consent
Cookie Settings
We use cookies so that we can offer you the best possible website experience. This includes cookies which are necessary for the operations of the website, as well as cookies that are only used for anonymous statistical purposes, for comfort settings or to display personalized content. Please note that based on your settings, it is possible that not all functionalities of the website will be available. You can find further information in our Privacy Policy
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}